For which kind of rejection reaction does Besudil/Yilaike have a significant effect?

Belumosudil mesylate tablets (Belumosudil) is an oral small molecule drug targeting Rho-associated protein kinase 2 (ROCK2), which has shown significant efficacy in the treatment of chronic graft-versus-host disease (cGvHD). Chronic GvHD is one of the most common immune rejection reactions after bone marrow or hematopoietic stem cell transplantation. Traditional immunosuppressive treatment has limited effect in some patients, especially those who are unresponsive or resistant to previous standard treatments. By selectively inhibiting ROCK2, Besudil regulates T cell function and reduces the production of pro-inflammatory cytokines, thereby inhibiting the immune system's attack on transplanted tissues and alleviating the symptoms of multi-organ involvement.

Clinical studies have shown that Besudil can play a role in improving the function of multiple affected organs such as the skin, liver, oral cavity and lungs. Its unique mechanism of action can not only reduce the inflammatory response, but also reduce the risk of side effects of long-term use of glucocorticoids and traditional immunosuppressants to a certain extent. For patients with refractory chronic GvHD, the remission rate and overall response rate of besudil are significantly higher than those of traditional treatments, especially in those patients who have insufficient response to conventional treatments.

The oral administration method of besudil also provides patients with convenience. Compared with intravenous immunosuppressive drugs, its use is more flexible. Patients can complete treatment at home or in an outpatient setting, and it also facilitates long-term management of rejection. The side effects of the drug are generally controllable, with mild to moderate fatigue, diarrhea, muscle pain and slight abnormalities in hematological indicators being common. The incidence of serious adverse events is low, providing patients with a safe long-term medication option.

To sum up, besudil is particularly effective in the treatment of chronic graft-versus-host disease, and is especially suitable for patients who are ineffective or resistant to standard immunosuppressive regimens. It regulates the immune response through the ROCK2 signaling pathway, which not only improves symptoms, but also reduces the risk of side effects of traditional drugs, providing a new and effective treatment approach for long-term management of transplant rejection.

Reference: https://www.drugs.com/pro/rezurock.html